menu ☰
menu ˟

Oyster Point's dry eye treatment shows positive phase 2b trial results

12 Jul 2018
Oyster Point Pharma’s dry eye disease treatment met both sign and symptom primary endpoints in a phase 2b clinical trial, the company announced in a press release.OC-02, a nicotinic acetylcholine receptor agonist, is delivered as a nasal spray and ...

Click here to view the full article which appeared in Opthalmology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.